8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Metagenomi, Inc. Common Stock(MGX)Earnings, Financials & Key Ratios
MGX•NASDAQ
Price updated Jun 19, 2026
AboutMetagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Show more
- Revenue$25M-51.8%
- EBITDA-$91M-8.6%
- Net Income-$88M-12.6%
- EPS (Diluted)-2.36-12.9%
- Gross Margin78.91%-21.1%
- EBITDA Margin-359.76%-125.3%
- Operating Margin-380.85%-124.0%
- Net Margin-348.54%-133.5%
- ROE-44.67%-28.8%
MGX Key Insights
Metagenomi, Inc. Common Stock (MGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MGX Price & Volume
Metagenomi, Inc. Common Stock (MGX) stock price & volume — 10-year historical chart
Loading chart...
MGX Growth Metrics
Metagenomi, Inc. Common Stock (MGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years13.59%
TTM-50.66%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-9%
Return on Capital
10 Years-26.55%
5 Years-26.55%
3 Years-31.25%
Last Year-39.56%
MGX Recent Earnings
Metagenomi, Inc. Common Stock (MGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)●Beat Revenue 7/12 qtrs (70%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.61-1.7%
$0.60
Rev
$1M-78.9%
$6M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.60-3.4%
$0.58
Rev
$4M-46.6%
$7M
Q4 2025
Nov 11, 2025Metric
Actual
Est
EPS
$0.55+8.3%
$0.60
Rev
$9M+10.7%
$8M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.54+20.6%
$0.68
Rev
$9M+7.2%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.61vs $0.60-1.7% | $1Mvs $6M-78.9% |
| Q2 2026 | Mar 5, 2026 | $0.60vs $0.58-3.4% | $4Mvs $7M-46.6% |
| Q4 2025 | Nov 11, 2025 | $0.55vs $0.60+8.3% | $9Mvs $8M+10.7% |
| Q3 2025 | Aug 12, 2025 | $0.54vs $0.68+20.6% | $9Mvs $8M+7.2% |
Based on last 12 quarters of dataView full earnings history →
MGX Peer Comparison
Metagenomi, Inc. Common Stock (MGX) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 PRME | 583.39M | 3.23 | -2.39 | 55.28% | -49.18% | -188.82% | 0.96 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare MGX vs Peers
Metagenomi, Inc. Common Stock (MGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGX Income Statement
Metagenomi, Inc. Common Stock (MGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 243K | 17.2M | 44.76M | 52.3M | 25.21M | 22.33M |
Revenue Growth % | - | 6978.19% | 160.21% | 16.84% | -51.79% | -50.66% |
Cost of Goods Sold | 387K | 1.73M | 94.4M | 0 | 5.32M | 25.13M |
COGS % of Revenue | 159.26% | 10.08% | 210.93% | - | 21.09% | - |
Gross Profit | -144K▲ 0% | 15.47M▲ 10841.0% | -49.65M▼ 421.0% | 52.3M▲ 205.3% | 19.89M▼ 62.0% | -2.8M▲ 0% |
Gross Margin % | -59.26% | 89.92% | -110.93% | 100% | 78.91% | -12.54% |
Gross Profit Growth % | - | 10840.97% | -420.99% | 205.33% | -61.96% | - |
Operating Expenses | 23.8M | 60.11M | 28.84M | 141.2M | 115.91M | 89.98M |
OpEx % of Revenue | 9795.47% | 349.46% | 64.45% | 270% | 459.76% | - |
Selling, General & Admin | 9.71M | 18.7M | 28.84M | 32.02M | 26.79M | 25.22M |
SG&A % of Revenue | 3996.71% | 108.73% | 64.45% | 61.22% | 106.27% | - |
Research & Development | 14.48M | 43.14M | 94.4M | 109.18M | 94.43M | 87.27M |
R&D % of Revenue | 5958.02% | 250.81% | 210.93% | 208.78% | 374.59% | - |
Other Operating Expenses | -387K | -1.73M | -94.4M | 0 | -5.32M | -1000K |
Operating Income | -23.95M▲ 0% | -44.64M▼ 86.4% | -78.49M▼ 75.8% | -88.9M▼ 13.3% | -96.01M▼ 8.0% | -92.78M▲ 0% |
Operating Margin % | -9854.73% | -259.53% | -175.38% | -170% | -380.85% | -415.48% |
Operating Income Growth % | - | -86.41% | -75.83% | -13.26% | -8% | - |
EBITDA | -23.56M | -42.91M | -74.28M | -83.49M | -90.7M | -87.28M |
EBITDA Margin % | -9695.47% | -249.46% | -165.98% | -159.66% | -359.76% | -390.86% |
EBITDA Growth % | - | -82.12% | -73.13% | -12.4% | -8.63% | -6.19% |
D&A (Non-Cash Add-back) | 387K | 1.73M | 4.21M | 5.41M | 5.32M | 3.96M |
EBIT | -21.14M | -40.93M | -78.49M | -88.9M | -96.01M | -89.03M |
Net Interest Income | -259K | 3.32M | 15.47M | 14.72M | 9.47M | 8.12M |
Interest Income | 43K | 3.42M | 15.47M | 14.72M | 9.47M | 8.12M |
Interest Expense | 302K | 98K | 0 | 0 | 0 | 0 |
Other Income/Expense | 2.5M | 3.62M | 18.26M | 5.33M | 8.09M | 6.75M |
Pretax Income | -21.44M▲ 0% | -41.02M▼ 91.3% | -60.23M▼ 46.8% | -83.57M▼ 38.8% | -87.93M▼ 5.2% | -86.03M▲ 0% |
Pretax Margin % | -8823.87% | -238.51% | -134.57% | -159.81% | -348.77% | -385.27% |
Income Tax | 0 | 2.57M | 8.03M | -5.51M | -58K | -166K |
Effective Tax Rate % | 0% | -6.26% | -13.33% | 6.6% | 0.07% | 0.19% |
Net Income | -21.44M▲ 0% | -43.59M▼ 103.3% | -68.25M▼ 56.6% | -78.06M▼ 14.4% | -87.87M▼ 12.6% | -85.89M▲ 0% |
Net Margin % | -8823.87% | -253.45% | -152.5% | -149.26% | -348.54% | -384.61% |
Net Income Growth % | - | -103.31% | -56.57% | -14.36% | -12.57% | -10.18% |
Net Income (Continuing) | -21.44M | -43.59M | -68.25M | -78.06M | -87.87M | -85.87M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.62▲ 0% | -1.16▲ 68.0% | -1.82▼ 56.9% | -2.09▼ 14.8% | -2.36▼ 12.9% | -2.29▲ 0% |
EPS Growth % | - | 67.96% | -56.9% | -14.84% | -12.92% | -9% |
EPS (Basic) | -3.62 | -1.16 | -1.82 | -2.09 | -2.36 | - |
Diluted Shares Outstanding | 5.93M | 37.47M | 37.47M | 37.42M | 37.25M | 37.58M |
Basic Shares Outstanding | 5.93M | 37.47M | 37.47M | 37.42M | 37.25M | 37.58M |
Dividend Payout Ratio | - | - | - | - | - | - |
MGX Balance Sheet
Metagenomi, Inc. Common Stock (MGX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 108.92M | 366.9M | 278.27M | 257.96M | 165.54M | 144.56M |
Cash & Short-Term Investments | 108.15M | 362.13M | 271.18M | 248.31M | 160.8M | 140.16M |
Cash Only | 39.3M | 184.44M | 140.6M | 27.39M | 41.72M | 25.31M |
Short-Term Investments | 68.86M | 177.69M | 130.58M | 220.92M | 119.08M | 114.86M |
Accounts Receivable | 490K | 1.27M | 2.45M | 1.26M | 305K | 0 |
Days Sales Outstanding | 736.01 | 27.04 | 19.99 | 8.77 | 4.42 | 8.74 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 272K | 2.81M | 4.64M | 8.4M | 4.43M | 4.4M |
Total Non-Current Assets | 33.08M | 47.59M | 86.57M | 66.64M | 55.56M | 52.4M |
Property, Plant & Equipment | 22.14M | 33.26M | 65.15M | 57.66M | 47.38M | 44.92M |
Fixed Asset Turnover | 0.01x | 0.52x | 0.69x | 0.91x | 0.53x | 0.46x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 6.42M | 7.81M | 15.92M | 3.45M | 2.15M | 8.62M |
Other Non-Current Assets | 4.52M | 6.52M | 5.49M | 5.54M | 6.03M | 5.32M |
Total Assets | 141.99M▲ 0% | 414.49M▲ 191.9% | 364.84M▼ 12.0% | 324.6M▼ 11.0% | 221.1M▼ 31.9% | 196.95M▲ 0% |
Asset Turnover | 0.00x | 0.04x | 0.12x | 0.16x | 0.11x | 0.10x |
Asset Growth % | - | 191.91% | -11.98% | -11.03% | -31.88% | -126.02% |
Total Current Liabilities | 25.17M | 48.54M | 68.86M | 37.31M | 22.93M | 22.5M |
Accounts Payable | 1.35M | 2.01M | 1.79M | 533K | 1.49M | 2.4M |
Days Payables Outstanding | 1.28K | 423.55 | 6.92 | - | 102.22 | 29.02 |
Short-Term Debt | 0 | 0 | 3.43M | 0 | 6.03M | 6.11M |
Deferred Revenue (Current) | 16.04M | 33.94M | 48.91M | 22.76M | 8.7M | 49.85M |
Other Current Liabilities | 5.8M | 5.56M | 4.21M | 5.35M | 6.72M | 4.69M |
Current Ratio | 4.33x | 7.56x | 4.04x | 6.91x | 7.22x | 6.43x |
Quick Ratio | 4.33x | 7.56x | 4.04x | 6.91x | 7.22x | 6.43x |
Cash Conversion Cycle | - | - | - | - | - | -20.29 |
Total Non-Current Liabilities | 149.36M | 440.38M | 80.81M | 52.43M | 39.57M | 36.67M |
Long-Term Debt | 30.28M | 0 | 0 | 0 | 0 | 33.08M |
Capital Lease Obligations | 17.96M | 17.06M | 44.8M | 40.19M | 34.63M | 108.21M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 77.41M | 347.14M | 5.08M | 2.01M | 1.95M | 3.59M |
Total Liabilities | 174.54M | 488.91M | 149.67M | 89.74M | 62.51M | 59.17M |
Total Debt | 48.93M | 18.57M | 48.23M | 45.78M | 40.66M | 39.19M |
Net Debt | 9.63M | -165.87M | -92.37M | 18.39M | -1.06M | 13.88M |
Debt / Equity | - | - | 0.22x | 0.19x | 0.26x | 0.28x |
Debt / EBITDA | - | - | - | - | - | -0.45x |
Net Debt / EBITDA | - | - | - | - | - | -0.16x |
Interest Coverage | -70.00x | -417.61x | - | - | - | - |
Total Equity | -32.54M▲ 0% | -74.43M▼ 128.7% | 215.17M▲ 389.1% | 234.86M▲ 9.1% | 158.6M▼ 32.5% | 137.78M▲ 0% |
Equity Growth % | - | -128.7% | 389.1% | 9.15% | -32.47% | -125.23% |
Book Value per Share | -5.49 | -1.99 | 5.74 | 6.28 | 4.26 | 3.67 |
Total Shareholders' Equity | -32.54M | -74.43M | 215.17M | 234.86M | 158.6M | 137.78M |
Common Stock | 573K | 2.54M | 26K | 4K | 4K | 4K |
Retained Earnings | -33.1M | -76.69M | -144.94M | -223M | -310.87M | -333.93M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -21K | -274K | 9.33M | 709K | 260K | -44K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
MGX Cash Flow Statement
Metagenomi, Inc. Common Stock (MGX) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | 24.26M | 29.72M | -91.41M | -109.07M | -88.89M | -87.22M |
Operating CF Margin % | 9982.3% | 172.81% | -204.24% | -208.57% | -352.61% | - |
Operating CF Growth % | - | 22.54% | -407.53% | -19.32% | 18.5% | 57.13% |
Net Income | -21.44M | -43.59M | -68.25M | -78.06M | -87.87M | -85.89M |
Depreciation & Amortization | 387K | 1.73M | 4.21M | 5.41M | 5.32M | 5.23M |
Stock-Based Compensation | 375K | 1.96M | 6.92M | 16.2M | 11.85M | 8.93M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -1.32M | 135K | -7.85M | 7.04M | 3.9M | 7.24M |
Working Capital Changes | 46.26M | 69.49M | -26.43M | -59.67M | -22.09M | -22.73M |
Change in Receivables | 0 | -1.27M | -1.18M | 1.19M | 952K | 1.01M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 695K | 721K | -84K | -1.11M | 1.05M | -361K |
Cash from Investing | -74.32M | -122.2M | 45.73M | -88.16M | 103.53M | 82.79M |
Capital Expenditures | -2.9M | -13.98M | -9.81M | -3.11M | -574K | -311K |
CapEx % of Revenue | 1194.65% | 81.26% | 21.93% | 5.95% | 2.28% | 1.39% |
Acquisitions | 0 | 0 | 0 | 0 | 37K | 37K |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 3M | 470K |
Cash from Financing | 39.92M | 239.59M | 1.01M | 84.01M | -356K | -306K |
Debt Issued (Net) | 29.97M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 9.95M | 239.59M | 4.29M | 84.01M | 202K | 202K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -3.28M | 0 | -558K | -508K |
Net Change in Cash | -10.14M▲ 0% | 147.12M▲ 1551.3% | -44.66M▼ 130.4% | -113.22M▼ 153.5% | 14.28M▲ 112.6% | -3.94M▲ 0% |
Free Cash Flow | 21.35M▲ 0% | 15.75M▼ 26.3% | -101.22M▼ 742.8% | -112.19M▼ 10.8% | -89.47M▲ 20.3% | -87.54M▲ 0% |
FCF Margin % | 8787.65% | 91.55% | -226.17% | -214.53% | -354.88% | -391.99% |
FCF Growth % | - | -26.26% | -742.81% | -10.83% | 20.25% | 16.28% |
FCF per Share | 3.60 | 0.42 | -2.70 | -3.00 | -2.40 | -2.33 |
FCF Conversion (FCF/Net Income) | -1.13x | -0.68x | 1.34x | 1.40x | 1.01x | 1.02x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 2.25M | 3.5M | 0 | 0 |
MGX Key Ratios
Metagenomi, Inc. Common Stock (MGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | - | -96.99% | -34.69% | -44.67% | -51.23% |
Return on Invested Capital (ROIC) | - | -47.94% | -35.46% | -35.06% | -39.29% |
Gross Margin | 89.92% | -110.93% | 100% | 78.91% | -12.54% |
Net Margin | -253.45% | -152.5% | -149.26% | -348.54% | -384.61% |
Debt / Equity | - | 0.22x | 0.19x | 0.26x | 0.28x |
Interest Coverage | -417.61x | - | - | - | - |
FCF Conversion | -0.68x | 1.34x | 1.40x | 1.01x | 1.02x |
Revenue Growth | 6978.19% | 160.21% | 16.84% | -51.79% | -50.66% |
Related:MGX Dividend History·MGX Revenue History·MGX Price History·MGX P/E History·MGX Financial Ratios·MGX Institutional Holders
MGX SEC Filings & Documents
Metagenomi, Inc. Common Stock (MGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
MGX Frequently Asked Questions
Metagenomi, Inc. Common Stock (MGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Metagenomi, Inc. Common Stock (MGX) reported $22.3M in revenue for fiscal year 2025. This represents a 9090% increase from $0.2M in 2021.
Metagenomi, Inc. Common Stock (MGX) saw revenue decline by 51.8% over the past year.
Metagenomi, Inc. Common Stock (MGX) reported a net loss of $85.9M for fiscal year 2025.
Dividend & Returns
Metagenomi, Inc. Common Stock (MGX) has a return on equity (ROE) of -44.7%. Negative ROE indicates the company is unprofitable.
Metagenomi, Inc. Common Stock (MGX) had negative free cash flow of $87.5M in fiscal year 2025, likely due to heavy capital investments.